Richard Schilsky to Patient Selection
This is a "connection" page, showing publications Richard Schilsky has written about Patient Selection.
Connection Strength
1.135
-
Modernizing Eligibility Criteria for Molecularly Driven Trials. J Clin Oncol. 2015 Sep 01; 33(25):2815-20.
Score: 0.347
-
How not to treat cancer. Lancet Oncol. 2008 Jun; 9(6):504-5.
Score: 0.212
-
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. Eur J Cancer. 2018 09; 100:35-45.
Score: 0.106
-
Improving evidence developed from population-level experience with targeted agents. Clin Pharmacol Ther. 2015 May; 97(5):478-87.
Score: 0.085
-
Precision cancer medicine: the future is now, only better. Am Soc Clin Oncol Educ Book. 2014; 61-9.
Score: 0.078
-
American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol. 2013 Dec 01; 31(34):4362-70.
Score: 0.077
-
Development and use of integral assays in clinical trials. Clin Cancer Res. 2012 Mar 15; 18(6):1540-6.
Score: 0.069
-
Accrual to cancer clinical trials in the era of molecular medicine. Sci Transl Med. 2011 Mar 23; 3(75):75cm9.
Score: 0.064
-
American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009 Apr 20; 27(12):2091-6.
Score: 0.055
-
Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. J Clin Oncol. 2016 11 20; 34(33):3992-3999.
Score: 0.024
-
Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008 Nov 01; 26(31):5043-51.
Score: 0.014
-
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst. 1993 Oct 20; 85(20):1637-43.
Score: 0.005